The Everolimus-Transplant Exit Strategy Trial (E-TEST)
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of everolimus (Zortress®)
in preventing antibody formation in patients with chronic failing kidney transplants.
Everolimus (Zortress®) is approved by the U.S. Food and Drug Administration for the
prevention of rejection in kidney transplant.
The primary objective for the study is to determine whether conversion of patients with
chronic renal graft failure approaching dialysis to an everolimus-based regimen will prevent
allosensitization. The secondary objective will be to determine whether conversion of
patients with chronic renal graft failure to everolimus (elimination of calcineurin
inhibitor) will delay the onset of dialysis.